Welcome to our dedicated page for Ptc Therapeutics news (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on Ptc Therapeutics stock.
PTC Therapeutics develops and commercializes medicines for children and adults with rare disorders, with a life-science business focused on clinically differentiated therapies in areas including neurology and metabolism. Company news commonly covers product revenue, commercial launch activity, financial guidance, investor presentations, and updates from its rare-disease development portfolio.
Recurring developments include Sephience™ (sepiapterin) launch and revenue updates, clinical and regulatory disclosures involving votoplam, vatiquinone and Translarna™ (ataluren), and partnership-related program responsibilities. PTC also reports governance changes and Nasdaq inducement equity grants tied to employee compensation.
PTC Therapeutics (NASDAQ: PTCT) reported Q1 2026 total revenue of $273M, including $226M product revenue, and raised full‑year product revenue guidance to $750–$850M with total revenue guidance of $1.08–$1.18B. Sephience revenue was $124.6M (36% QoQ). Q1 GAAP R&D was $100.9M; GAAP SG&A was $86.2M. Net loss was $2.8M. Cash and marketable securities were $1.892B at March 31, 2026. Clinical updates include positive 24‑month PIVOT‑HD topline results for votoplam and plans to start an open‑label vatiquinone registration study in Q3 2026.
PTC Therapeutics (NASDAQ: PTCT) announced executive presentations at three investor conferences in May–June 2026. Scheduled appearances: Bank of America Health Care Conference on May 12, RBC Capital Markets Global Healthcare on May 20, and Goldman Sachs Global Healthcare Conference on June 9.
Each presentation will be webcast live and archived for 30 days on PTC Therapeutics' investor Events and Presentations page.
PTC Therapeutics (NASDAQ: PTCT) reported positive topline results from the 24-month interim analysis of the PIVOT-HD extension study of votoplam in Huntington's disease on April 28, 2026. Stage 2 participants showed dose-dependent slowing on the cUHDRS: 52% slowing at 10 mg and 28% at 5 mg versus a propensity-weighted natural history cohort.
Mean NfL remained below baseline at 24 months for both doses; safety at Month 24 was consistent with prior data. Novartis has initiated the global Phase 3 INVEST-HD study (≈770 participants, 3:2 randomization to 10 mg or placebo).
PTC Therapeutics (NASDAQ: PTCT) will report results from the 24-month interim analysis of the PIVOT-HD long-term extension study of votoplam on April 28, 2026.
The company will host a webcast and conference call today at 4:30 p.m. ET. Novartis said the long-term data support its now-initiated Phase 3 INVEST-HD study; Novartis and PTC will assess next steps, including possible actions with the FDA.
Live access and a 30-day replay are available on the Investors & Events page; phone participation requires advance registration.
PTC Therapeutics (NASDAQ: PTCT) will report first quarter 2026 financial results on Thursday, May 7, 2026 at 4:30 p.m. ET via a live webcast and conference call. The company will provide a business update and outlook during the event.
A replay will be available on the company's Investors "Events & Presentations" page for 30 days; phone participation requires advance registration for dial-in details.
PTC Therapeutics (NASDAQ: PTCT) announced inducement equity grants approved April 13, 2026 for a new non-executive employee under Nasdaq Listing Rule 5635(c)(4).
The company granted non-statutory stock options to purchase 1,155 shares and 925 RSUs. Options have a $70.42 exercise price, 10-year term, and four-year vesting schedules; RSUs vest over four years.
PTC Therapeutics (NASDAQ: PTCT) appointed Jessica Chutter to its Board of Directors on March 25, 2026. Ms. Chutter recently retired as Managing Director and Chair of Biotechnology Investment Banking at Morgan Stanley after a 40+ year career. She was involved in approximately $80 billion of capital raising and $85 billion of strategic transactions. Management said Ms. Chutter advised PTC previously and will help guide the company’s next stage of growth.
PTC Therapeutics (NASDAQ: PTCT) approved inducement equity awards on March 10, 2026, for 18 new employees: 14,550 non‑statutory stock options and 17,515 restricted stock units (RSUs) as hiring incentives under Nasdaq Listing Rule 5635(c)(4).
Options carry a $68.56 exercise price, a 10‑year term, and four‑year vesting (25% after one year, then quarterly 6.25%). RSUs vest over four years with 25% vesting each anniversary, all subject to continued service.
PTC Therapeutics (NASDAQ: PTCT) said executives will present at three investor conferences in early March 2026: TD Cowen on March 2, Leerink on March 10, and Barclays on March 11.
All presentations will be webcast live via the company’s Events and Presentations page and archived for 30 days. Viewers are advised to connect several minutes early.
PTC Therapeutics (NASDAQ: PTCT) reported full-year 2025 product and royalty revenue of $831M, total 2025 revenues of $1.731B, and cash of $1.945B at year-end. Sephience launched in 2H 2025, generating $111M in 2025 and $92M in Q4. PTC closed a royalty sale for Evrysdi for $240M upfront and up to $60M in milestones. Full-year 2025 net income was $682.6M driven by a Novartis collaboration payment; GAAP R&D and SG&A guidance given for 2026.